<DOC>
	<DOCNO>NCT01197534</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness two dosing regimen fostamatinib compare placebo , patient rheumatoid arthritis ( RA ) take disease modify anti-rheumatic drug ( DMARD ) respond . The study last 1 year .</brief_summary>
	<brief_title>Evaluation Effectiveness Two Dosing Regimens Fostamatinib Compared Placebo Patients With Rheumatoid Arthritis ( RA ) Who Are Taking Disease Modifying Anti-rheumatic Drug ( DMARD ) But Not Responding .</brief_title>
	<detailed_description>Sub-study : Full title : Optional Genetic Research Date : 18 June 2010 Version : 1 Objectives : To collect store , appropriate consent , DNA sample future exploratory research genes/genetic variation may influence response ( ie , absorption , distribution , metabolism excretion , safety , tolerability efficacy ) fostamatinib disodium and/or methotrexate ; and/or susceptibility , progression prognosis RA</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Active rheumatoid arthritis ( RA ) diagnose age 16 Treatment one follow disease modify antirheumatic drug : methotrexate , sulfasalazine , hydroxychloroquine chloroquine 4 swollen joint 4 tender/painful joint ( 28 joint count ) either Erythrocyte Sedimentation Rate ( ESR ) blood result 28mm/h , CReactive Protein ( CRP ) blood result 10mg/L At least one following : documented history positive rheumatoid factor ( blood test ) , current presence rheumatoid factor ( blood test ) , radiographic erosion within 12 month prior study enrolment , presence serum anticyclic citrullinated peptide antibody ( blood test ) Females pregnant breast feed Poorly control hypertension Liver disease significant liver function test abnormality Certain inflammatory condition ( rheumatoid arthritis ) , connective tissue diseases chronic pain disorder Recent significant cardiovascular disease Significant active recent infection include tuberculosis Previous failure respond TNF alpha antagonist , anakinra previous treatment biological agent Severe renal impairment Neutropenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>